.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a typical follow-up of 11 months, people along with metastatic gastrointestinal tumors who obtained biomarker-matched treatments based upon distributing tumor DNA profiling showed a greater scientific advantage than those acquiring unparalleled therapy.